Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 9, 2017. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price | Volume |
|---|---|---|---|
| 2017-02-08 | Ordinary Shares (GBP) | £15.55 | 1,366.302 (Aggregate) |
| 2017-02-08 | American Depositary Shares (USD) | $39.46 | 1,803.551 (Aggregate) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine compliance disclosures for share acquisitions by directors.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described are acquisitions of notional shares resulting from the annual reinvestment of dividends paid to shareholders throughout 2016 under share allocation arrangements for Independent Non-Executive Directors.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions are dividend reinvestments, not open market purchases or sales.
- Participants: Transactions involve the Non-Executive Chairman and six Independent Non-Executive Directors (Sir Philip Hampton, Professor Sir Roy Anderson, Mr Vindi Banga, Dr Vivienne Cox, Ms Lynn Elsenhans, Ms Judy Lewent, and Mr Urs Rohner).
- Share Classes: Transactions occurred in both Ordinary Shares (ISIN: GB0009252882) and American Depositary Shares (ISIN: US37733W1053).
- Timing: All transactions were executed on February 8, 2017.